Subcutaneous administration of isatuximab in patients with multiple myeloma by an on-body delivery system: Results of a nurse survey

A nurse survey evaluated subcutaneous isatuximab (Isa) administration via an on-body delivery system (OBDS) for multiple myeloma patients. Nurses expressed high confidence, preferring OBDS over intravenous administration due to its ease of use, improved efficiency, and low physical burden. They noted enhanced patient comfort, reduced clinic time, and decreased anxiety, suggesting its applicability in routine clinical practice.